Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression: A retrospective cohort study.

ABSTRACT:

Background

Breast cancer is the most prevalent cancer that causes significant morbidity and loss of productivity. Around a third of all breast cancer patients are potentially develop distant metastases albeit the current implementation of multidisciplinary treatment. A simple but effective marker to predict the risks of cancer progression is very important for clinicians to improve treatment and surveillance.

Methods

We recruited 1083 non-metastatic patients and analyzed the ratios of neutrophil to lymphocyte (NLR) and platelet to lymphocyte (PLR) in relation to progression-free survivals (PFS) and risks of distant metastases.

Results

Baseline clinicopathological variables were not significantly different in the pretreatment NLR and PLRs. Using maximum points of sensi

SUBMITTER: Anwar SL 

PROVIDER: S-EPMC7890158 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature